Histoire nouvelle du nouveau monde : contenant en somme ce que les Hespagnols ont fait jusqu'à présent aux Indes occidentales, & le rude traitement qu'ils font à ces poures peuples là : ensemble, une petite histoire d'un massacre commis par les Hespagnols sur quelques François en la Floride, avec un indice des choses les plus remarquables / extraite de l'italien de M. Hierosme Benzoni... par M. Urbain Chauveton ; par M. Urbain Chauveton

Comprend : Brief discours et histoire d'un voyage de quelques François en Floride : & du massacre autant injustement que barbarement executé sur eux, par les Hespagnols, l'an mil cinq cens soixante cinq

Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.

BACKGROUND: We aimed to compare panitumumab, a fully human monoclonal antibody against EGFR, plus radiotherapy with chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck. METHODS: In this international, open-label, randomised, controlled, phase 2 trial, we recruited patients with locally advanced squamous-cell carcinoma of the head and neck from 22 sites in eight countries worldwide. Patients aged 18 years and older with stage III, IVa, or IVb, previously untreated, measurable (≥10 mm for at least one dimension), locally advanced squamous-cell carcinoma of the head and neck (non-nasopharygeal) and an Eastern Cooperative Oncology Group performance status of 0-1 were randomly assigned (2:3) by an independent vendor to open-label chemoradiotherapy (two cycles of cisplatin 100 mg/m(2) during radiotherapy) or to radiotherapy plus panitumumab (three cycles of panitumumab 9 mg/kg every 3 weeks administered with radiotherapy) using a stratified randomisation with a block size of five. All patients received 70-72 Gy to gross tumour and 54 Gy to areas of subclinical disease with accelerated fractionation radiotherapy. The primary endpoint was local-regional control at 2 years, analysed in all randomly assigned patients who received at least one dose of their assigned protocol-specific treatment (chemotherapy, radiation, or panitumumab). The trial is closed and this is the final analysis. This study is registered with ClinicalTrials.gov, number NCT00547157. FINDINGS: Between Nov 30, 2007, and Nov 16, 2009, 152 patients were enrolled, and 151 received treatment (61 in the chemoradiotherapy group and 90 in the radiotherapy plus panitumumab group). Local-regional control at 2 years was 61% (95% CI 47-72) in the chemoradiotherapy group and 51% (40-62) in the radiotherapy plus panitumumab group. The most frequent grade 3-4 adverse events were mucosal inflammation (25 [40%] of 62 patients in the chemoradiotherapy group vs 37 [42%] of 89 patients in the radiotherapy plus panitumumab group), dysphagia (20 [32%] vs 36 [40%]), and radiation skin injury (seven [11%] vs 21 [24%]). Serious adverse events were reported in 25 (40%) of 62 patients in the chemoradiotherapy group and in 30 (34%) of 89 patients in the radiotherapy plus panitumumab group. INTERPRETATION: Panitumumab cannot replace cisplatin in the combined treatment with radiotherapy for unresected stage III-IVb squamous-cell carcinoma of the head and neck, and the role of EGFR inhibition in locally advanced squamous-cell carcinoma of the head and neck needs to be reassessed. FUNDING: Amgen.

Etat des chemins et routes les plus praticables pour entrer dans la vallée et chateau de Queyras, et les differents cols par ou l'on peut penetrer dans les Etats du Roy de Sardaigne dans le Piedmont

Ancien possesseur : Argenson, Antoine-René de Voyer (1722-1787 ; marquis de Paulmy d')

Assessment of the in vitro synergy of daptomycin plus linezolid against multidrug-resistant enterococci

The widespread incidence of enterococci resistant to ampicillin, vancomycin and aminoglycosides, the first-line anti-enterococcal antibiotics, has made the treatment of severe enterococcal infections difficult and alternatives should be explored. We investigated the activity of daptomycin combined with linezolid against three Enterococcus faecalis and four Enterococcus faecium strains resistant to standard drugs used for therapy. Minimum inhibitory concentrations (MICs) were determined by the broth dilution method. Drug interactions were assessed by the checkerboard and time-kill methods. Synergy was defined by a fractional inhibitory concentration index (FICI) of ≤0.5 or a ≥2 log10 CFU/mL killing at 24 h with the combination in comparison with killing by the most active single agent. Indifference was defined by a FICI > 0.5-4.0 or a 1-2 log10 CFU/mL killing compared with the most active single agent. MICs of daptomycin were 2-4 μg/mL for E. faecalis and 2-8 μg/mL for E. faecium. MICs of linezolid were 1-2 μg/mL for all bacteria. In the checkerboard assay, five isolates showed synergism (FICI < 0.5) and two showed indifference (FICIs of 0.53 and 2). Killing studies revealed synergy of daptomycin plus linezolid against four isolates (2.2-3.7 log10 CFU/mL kill) and indifference (1.1-1.6 log10 CFU/mL kill) for the other three strains. Antagonism was not observed. In conclusion, the combination of daptomycin and linezolid had a synergistic or indifferent effect against multidrug-resistant enterococci. Additional studies are needed to explore the potential of this combination for severe enterococcal infections when first-line antibiotic combinations cannot be used.

Tecnologia VOIP com Asterisk (UM@STERISK)

Este trabalho trata do software livre Asterisk (Elastix), uma central telefónica privada IP ou (PBX IP) que suporta inúmeros protocolos e codecs da tecnologia de voz sobre IP, Abordando a sua instalação, configuração e compatibilidade com hardware de telefonia. O crescimento das redes IP, as técnicas avançadas de digitalização de voz e os mecanismos que permitem a qualidade dos serviços, permitiram a consolidação da telefonia IP. A telefonia IP está em todo-poderoso crescimento, pois além de reduzir os custos das ligações telefónicas, ela permite a ligação entre as redes de dados e de voz, criando uma infra-estrutura única, facilitando a instalação, a manutenção e o gerenciamento. Este trabalho tem como objetivo fazer um estudo da Tecnologia VoIP (Voz sob IP), propor uma estrutura e implementar um ambiente de teste, uma central telefónica VoIP com o uso do Asterisk. A central telefónica VoIP baseada no software livre Asterisk possibilita a interligação de localidades geograficamente distantes uma das outras através das redes IP, sem a necessidade de pagar os altos valores cobrados pelos fabricantes de centrais telefónicas, de hardware proprietário, pela manutenção, fornecimento de equipamentos e licenças, mas permite que se obtenha os mesmos resultados, como por exemplo, que todos os Funcionários e ou colaboradores de uma empresa realizem chamadas telefónicas entre si sem precisar pagar altas taxas cobradas pelas operadoras de telefonia pública. Através da pesquisa bibliográfica sobre a tecnologia VoIP e do estudo do software livre Asterisk, será proposta a implantação da tecnologia através da implementação de um central VoIP. A verificação dessa implantação será realizada através de testes práticos em um ambiente que será desenvolvido.